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ABSTRACT
Background: Lansoprazole, a benzimidazole derivative, is indicated for the 
treatment of various peptic diseases. It is metabolized mainly in the liver, and its pri-
mary active metabolites present in plasma are 5′-hydroxy lansoprazole and lansopra- 
zole sulfone. Few data are available on the pharmacokinetic properties of lansoprazole, 
5′-hydroxy lansoprazole, and lansoprazole sulfone, which can be used to measure cyto-
chrome P450 (CYP) 2C19 activity.
Objectives: The aims of this study were to investigate the clinical plasma 
pharmacokinetic properties of lansoprazole and its metabolites in healthy Chinese 
male volunteers, and to assess the influences of CYP2C19 on the pharmacokinetics of 
lansoprazole.
Methods: Healthy adult Chinese male volunteers were enrolled in this single-
dose, open-label study. All patients received a single oral enteric capsule containing 
30 mg of lansoprazole after a 12-hour overnight fast. Serial blood samples were col-
lected immediately before (0 hour) and at 20, 40, 60, 90, 120, and 150 minutes and 3, 
4, 6, 8, 10, 12, 15, and 24 hours after study drug administration. The plasma concentra-
tions of lansoprazole, 5′-hydroxy lansoprazole, and lansoprazole sulfone were determined 
using a validated internal standard high-performance liquid chromatography–tandem 
mass spectrometry (HPLC-MS/MS) method. Pharmacokinetic properties (includ-
ing Cmax, Tmax, elimination t1/2 [t1/2z], mean residence time [MRT], AUC0–24, 
AUC0–∞, apparent oral clearance [CLz/F], and apparent volume of distribution 
[Vz/F]) were determined using the noncompartmental method.
Results: Twenty volunteers (mean [SD] age, 34.9 [2.9] years; weight, 64.6 
[2.2] kg; height, 171.3 [3.3] cm) were enrolled in and completed the study. The 
mean (SD) pharmacokinetic properties of lansoprazole were as follows: Cmax, 1047 
(344) ng/mL; Tmax, 2.0 (0.7) hours; t1/2z, 2.24 (1.43) hours; MRT, 3.62 (0.87) hours; 
AUC0–24, 3388 (1484) ng/mL/h; AUC0–∞, 3496 (1693) ng/mL/h; CLz/F, 9.96 (3.74) L/h; 
and Vz/F, 32.83 (11.74) L. The findings with 5′-hydroxy lansoprazole and lansopra-
zole sulfone, respectively, were as follows: Cmax, 111.2 (41.8) and 66.6 (52.9) ng/mL; 
Tmax, 2.1 (0.8) and 1.9 (0.8) hours; t1/2z, 2.31 (1.18) and 2.52 (1.54) hours; and 
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AUC0–24, 317.0 (81.2) and 231.9 (241.7) ng/mL/h. No adverse events were reported 
throughout the study.
Conclusions: In these healthy Chinese male volunteers administered a single 
oral dose of lansoprazole 30 mg, absorption of lansoprazole was rapid (mean Cmax, 
1047 ng/mL; Tmax, ~2.0 hours). Its 2 primary active metabolites, 5′-hydroxy lanso-
prazole and lansoprazole sulfone, were identified in measurable quantities in plasma 
(Cmax, 111.2 and 66.6 ng/mL, respectively; and Tmax, 2.1 and 1.9 hours). The plasma 
t1/2z did not appear to reflect the duration of suppression of gastric acid secretion: 
the t1/2z values of lansoprazole and the 2 metabolites were ~2 to 2.5 hours, while the 
acid-inhibitory effect lasted >24 hours. Cmax, AUC, and t1/2z of lansoprazole, and es-
pecially lansoprazole sulfone, varied. Differences in metabolism types and/or genotype 
of CYP2C19 should be taken into account when planning a lansoprazole dosing regi-
men. (Curr Ther Res Clin Exp. 2009;70:228–239) © 2009 Excerpta Medica Inc.
Key words: lansoprazole, 5′-hydroxy lansoprazole, lansoprazole sulfone, pharma- 
cokinetics, HPLC-MS/MS.
INTRODUCTION
Lansoprazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] 
benzimidazole, a benzimidazole derivative, is a proton pump inhibitor that acts on 
the membrane H+/K+-adenosine triphosphatase in gastric parietal cells.1 Lansopra-
zole is indicated for the treatment of various peptic diseases, including gastric and 
duodenal ulcer, reflux esophagitis, and Zollinger-Ellison syndrome.2 Lansoprazole is 
metabolized mainly in the liver, and its primary active metabolites present in plasma 
are 5′-hydroxy lansoprazole and lansoprazole sulfone. Formation of the 5′-hydroxy 
metabolite is mainly by cytochrome P450 (CYP) 2C19, whereas CYP3A4 is involved 
in the formation of the sulfone.3,4 The lansoprazole AUC values in poor metabolizers 
(PMs) of CYP2C19 have been found to be >4-fold greater than those in extensive 
metabolizers (EMs).5 The results from several clinical trials have suggested that the 
eradication rate of Helicobacter pylori is influenced by CYP2C19 activity6 based on 
higher plasma concentrations of lansoprazole and hence higher intragastric pH in 
PMs.7 Therefore, it is important to measure CYP2C19 activity using the hydroxyla-
tion and sulfoxidation indexes of lansoprazole, which reflect phenotype and genotype 
of the CYP2C19 isozyme8 from a clinical point of view. Few data are available on the 
pharmacokinetic properties of lansoprazole, 5′-hydroxy lansoprazole, and lansopra-
zole sulfone, which can be used to measure CYP2C19 activity. Simultaneous deter-
mination of the pharmacokinetic properties of lansoprazole and its 2 metabolites, 
described in this paper, may be more useful than determining those for lansopra- 
zole only, as in previously published studies,9–11 for the measurement of CYP2C19 
activity.
The pharmacokinetic properties of lansoprazole, 5′-hydroxy lansoprazole, and 
lansoprazole sulfone were investigated in healthy Chinese male volunteers, and 
the influences of CYP2C19 on the pharmacokinetics of lansoprazole were 
assessed.
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SUBJECTS AND METHODS
Study Design
This single-dose, open-label study was conducted at Xijing Hospital, Fourth 
Military Medical University, Xi’an, People’s Republic of China. The study proto-
col was approved by the ethics review committee at the hospital, in accordance 
with the principles of the Declaration of Helsinki and the recommendations of the 
State Food and Drug Administration of the People’s Republic of China (approval 
no. 2007L01026).
Inclusion and Exclusion Criteria
Healthy Chinese male volunteers were recruited from the local population by using 
newspaper advertisements. Subjects aged 18 to 40 years, weighing >50 kg, and with 
a body mass index of 19 to 24 kg/m2, were eligible. All subjects underwent a physical 
examination, electrocardiography (ECG), and laboratory analysis (hematology, bio-
chemistry, electrolytes, and urinalysis) at screening. Those found to have cardiac, he-
patic, renal, pulmonary, neurologic, gastrointestinal, or hematologic disease were ex-
cluded, as were those who had a smoking habit or drug or alcohol abuse or addiction 
(as determined by investigator inquiry, subject report, and urinary screening). Written 
informed consent was obtained from all subjects. Participants were compensated for 
their participation.
Study Drug Administration
After a 12-hour overnight fast (~8 am), subjects were administered a single oral 
enteric capsule containing 30 mg of lansoprazole* (lot no. 061001; expiration, August 
2011) with 250 mL of water. Standardized meals were administered 3 and 10 hours 
after study drug administration. Subjects were instructed to abstain from using any 
medication for 2 weeks before and during the study period. 
Determination of Plasma Concentrations of Lansoprazole and  
Its Metabolites
Venous blood samples (3.5 mL) were drawn immediately before (0 hour) and at 20, 
40, 60, 90, 120, and 150 minutes and 3, 4, 6, 8, 10, 12, 15, and 24 hours after study 
drug administration. Blood samples were collected into heparinized tubes and centri-
fuged immediately at 1000g at room temperature (20°C) for 10 minutes. The sepa-
rated plasma samples were stored at –70°C until analysis. 
The plasma concentrations of lansoprazole, 5′-hydroxy lansoprazole, and lansoprazole 
sulfone were determined using a validated internal standard (IS) high-performance 
liquid chromatography–tandem mass spectrometry (HPLC-MS/MS) method12 (2695 
LC system with a column oven [Waters Alliance, Milford, Massachusetts] coupled 
with a micro triple-quadruple mass spectrometer [Waters Quattro Micromass, Man-
chester, United Kingdom], equipped with an electrospray ion source and operated 
*Manufactured by Takeda Pharmaceutical Co., Ltd., Tianjin, People’s Republic of China.
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using MassLynx version 4.0 [Waters]). The reference standards of lansoprazole, 
5′-hydroxy lansoprazole, and lansoprazole sulfone were supplied by Jinglong Phar-
maTech (Nanjing, People’s Republic of China).
Briefly, the method was carried out as follows. All experiments, including sample 
preparation and instrumental analysis, were performed under feeble red light to pre-
vent photodegradation of the analytes. An aliquot of 0.5 mL of plasma in a plastic 
centrifuge tube was mixed with 50 μL of the IS solution (200 ng/mL indapamide, 
99.5% purity, National Institute for the Control of Pharmaceutical and Biological 
Products, Beijing, People’s Republic of China), then vortex-mixed with 1 mL of ace-
tonitrile (Tedia Co., Inc., Fairfield, Ohio) for 1 minute to precipitate the protein and 
extract the analytes. After centrifugation at 5°C with 16,800g for 10 minutes, an ali-
quot of 20 μL of the supernatant obtained was injected into the HPLC-MS/MS 
system.
LC separation was carried out using an Inertsil ODS-3 column (Varian Inc., Harbor 
City, California) (250 × 4.6-mm internal diameter; 5.0-μm particle size) preceded by 
an ODS guard column (4 × 2 mm) with a mixture of methanol and water (containing 
0.2% ammonium acetate and 0.1% formic acid) (75:25 vol/vol) (Nanjing Chemical 
Reagent Factory, Nanjing, People’s Republic of China) as mobile phase, eluted at a 
flow rate of 1.0 mL/min. The eluent was split so that 30% was introduced into the 
inlet of the mass spectrometer, and a valve was used to divert the eluent to waste from 
0 to 3 minutes. 
The mass spectrometer was operated in the positive electrospray ionization mode 
with selected reaction monitoring for the [M + H]+ ions. The spray voltage was 4 kV, 
and to increase the sensitivity and selectivity, collision-induced dissociation was used 
with argon as collision gas, and the collision energies were optimized to be 11, 13, 
and 22 eV for lansoprazole, 5′-hydroxy lansoprazole, and lansoprazole sulfone, re- 
spectively. The strongest transitions were selected as 370.1 to 252.1 m/z for lansopra-
zole, 386.1 to 252.1 m/z for 5′-hydroxy lansoprazole, 386.1 to 119.1 m/z for lanso-
prazole sulfone, and 366.1 to 132.1 m/z for IS. 
Pharmacokinetic Analysis
The pharmacokinetic parameters of lansoprazole and its metabolites were calcu-
lated using the noncompartmental method with the aid of the DAS program (Chinese 
Pharmacological Society, Beijing, People’s Republic of China). Cmax and Tmax were 
obtained directly from the observed concentration–time data. The terminal elimina-
tion rate constant (λz) was estimated by ln-linear regression of the terminal portion of 
the plasma concentration–time curves, and the elimination t1/2 (t1/2z) was calculated 
as 0.693/λz. The AUC0–24was estimated using numeric integration with the linear 
trapezoidal rule and extrapolated to infinity (AUC0–∞). The first moment of the 
plasma concentration–time curve, mean residence time (MRT), the statistical moment 
analogy to t1/2, was the estimation of the time for 63.2% of the administered dose to 
be eliminated. The apparent oral clearance (CLz/F) of lansoprazole was calculated as 
dose/AUC0–∞, while the apparent volume of distribution (Vz/F) was calculated as 
(CLz/F)/λz.
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Tolerability Assessment
Tolerability was assessed using physical examination, including vital sign monitor-
ing at 2, 24, and 72 hours after administration; laboratory analyses (hematology, 
biochemistry, and urinalysis); subject interview; and spontaneous reporting. The in-
vestigators rated adverse events as mild, moderate, or severe and determined their 
relationship to the study drug (unrelated, possibly related, or probably related).
HPLC-MS/MS Method Validation
Specificity was established using the lack of interference peaks at the retention time 
for the analytes. The calibration curve for lansoprazole, 5′-hydroxy lansoprazole, and 
lansoprazole sulfone in plasma was linear in the concentration ranges from 10 to 
4000, 5.0 to 400, and 1.0 to 400 ng/mL (r = 0.999), with the lower limits of quan-
titation of 2.0, 2.0, and 0.5 ng/mL, respectively. Mean recovery, expressed as the mean 
(SD) percentage of the spiked amount at the 3 quality control (QC) concentrations, were 
as follows: 98.7% (4.3%), 94.4% (0.5%), and 94.2% (4.6%) for lansoprazole; 105.8% 
(4.2%), 99.1% (3.7%), and 107.7% (2.7%) for 5′-hydroxy lansoprazole; and 98.4% 
(6.6%), 90.0% (0.9%), and 90.7% (3.4%) for lansoprazole sulfone. The interday 
%CVs for lansoprazole, 5′-hydroxy lansoprazole, and lansoprazole sulfone at the QC 
concentrations were 5.0 to 14.6, 4.7 to 14.2, and 10.0 to 14.5, respectively. The corre-
sponding intraday %CVs were 0.7 to 2.4, 0.9 to 2.0, and 0.9 to 2.0. 
The metabolites of lansoprazole are sensitive to light, and they may undergo photo-
degradation. Acetonitrile was used as solvent for stock solution preparation. The stock 
solutions were stable for at least 24 hours at 5°C and over a period of 30 days when 
stored at –70°C. In the stability experiment, plasma samples were stable over a period 
of 30 days when stored at –70°C and through 3 freeze–thaw cycles. The plasma 
samples handled as the method described earlier were stable for at least 24 hours at 
5°C when shaded from light.
RESULTS
Twenty healthy male volunteers (mean [SD] age, 34.9 [2.9] years; weight, 64.6 [2.2] kg; 
height, 171.3 [3.3] cm) were enrolled in and completed the study.
Pharmacokinetic Properties
The mean plasma concentration–time curves of lansoprazole, 5′-hydroxy lansopra-
zole, and lansoprazole sulfone after administration of a single oral dose of 30-mg 
lansoprazole are shown in the figure. The main pharmacokinetic parameters are 
shown in Table I. The mean (SD) pharmacokinetic properties of lansoprazole were as 
follows: Cmax, 1047 (344) ng/mL; Tmax, 2.0 (0.7) hours; t1/2z, 2.24 (1.43) hours; MRT, 
3.62 (0.87) hours; AUC0–24, 3388 (1484) ng/mL/h; AUC0–∞, 3496 (1693) ng/mL/h; 
CLz/F, 9.96 (3.74) L/h; and Vz/F, 32.83 (11.74) L. The findings with 5′-hydroxy lanso-
prazole and lansoprazole sulfone, respectively, were as follows: Cmax, 111.2 (41.8) and 
66.6 (52.9) ng/mL; Tmax, 2.1 (0.8) and 1.9 (0.8) hours; t1/2z, 2.31 (1.18) and 
2.52 (1.54) hours; and AUC0–24, 317.0 (81.2) and 231.9 (241.7) ng/mL/h. The mean 
(SD) fraction of 5′-hydroxy lansoprazole (calculated as [AUC0–24, 5′-hydroxy lansoprazole/
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AUC0–24, lansoprazole] × 100%) was 10.8% (4.5%), and that of lansoprazole sulfone 
was 5.9% (4.4%). The pharmacokinetic properties in individual subjects are shown in 
Table II. Some subjects (eg, subjects 5, 6, 9) had lower Cmax and AUC and higher 
CLz/F of lansoprazole, while some (eg, subjects 1, 13, 14) had the opposite.
Tolerability
No clinically significant changes in laboratory test results, vital sign measure-
ments, or ECG parameters were reported. No adverse events were reported or observed 
over the study period.
DISCUSSION
Because 5′-hydroxy lansoprazole and lansoprazole sulfone are the primary active me-
tabolites of lansoprazole, they should be determined simultaneously when the phar-
macokinetic properties and/or bioequivalence of lansoprazole is under study.
Mean (SD) Cmax values of lansoprazole, 5′-hydroxy lansoprazole, and lansoprazole sul- 
fone detected in this study were different from those reported in previously published stud- 
ies of the same dose: lansoprazole, 710 (266)11 to 2945 (1383)13 ng/mL; 5′-hydroxy 
lansoprazole, 73.5 (39.1)13 to 113.21 ng/mL; and lansoprazole sulfone, 131.11 to 169.2 
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Figure.  Plasma concentration–time profiles of lansoprazole, 5b-hydroxy lansoprazole, and 
lansoprazole sulfone after administration of a single oral enteric capsule of 30-mg 
lansoprazole in healthy male Chinese subjects (N = 20). Lower limits of quantita-
tion: 2.0, 2.0, and 0.5 ng/mL, respectively.
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(151.3) ng/mL.13 Different races of subjects and test conditions may have contrib-
uted to these differences. 
One of the reasons for the notable individual differences in the pharmacokinetic 
parameters of lansoprazole, and especially of its 2 metabolites, may have been the 
different metabolism types—EM and PM. In a single-dose study in 70 healthy volun-
teers (classified as EM or PM), it was reported that after the administration of a single 
oral dose of lansoprazole 30 mg, mean Cmax (1.10 and 1.73 μg/mL in EMs and PMs, 
respectively) and AUC (3.00 and 10.37 μg/mL/h) in the EMs were lower than those 
in the PMs and mean CLz/F (16.55 and 3.58 L/h) was higher in the EMs than the 
PMs (both, P < 0.01).10 Therefore, a dose <30 mg of lansoprazole in the PMs (eg, sub- 
jects 1, 13, 14 in the present study) would be sufficient for inhibiting acid secretion. 
Another reason for the differences in pharmacokinetic properties might have been 
the various genotypes and phenotypes of CYP2C19, a CYP mixed-function oxidase 
isozyme with high affinity and which plays a major role in the hydroxylation me-
tabolism of xenobiotics. Lansoprazole was hydroxylated under the mediation of 
CYP2C19 to form 5′-hydroxy lansoprazole. However, owing to the heterogenesis of 
CYP2C19m1 and CYP2C19m2, CYP2C19 produces different genotypes and phe-
notypes, such that the enzyme has different activity in individuals with different 
genotypes.9,10 Consequently, the pharmacokinetic properties of lansoprazole and its 
active metabolites may differ between people administered the same dose. Indi-
vidual differences should be taken into account when planning a lansoprazole dos-
ing regimen.
Although the adverse events most commonly (≥1%) reported with lansoprazole are 
diarrhea, abdominal pain, nausea, and constipation,14 no adverse events were reported 
in the present study.
Table I.  Pharmacokinetic properties of lansoprazole and its metabolites (5′-hydroxy 
lansoprazole and lansoprazole sulfone) after the administration of a single oral 
dose (30-mg enteric capsule) of lansoprazole in healthy male Chinese subjects 
(N = 20). Values are mean (SD).
  5′-Hydroxy Lansoprazole 
Parameter Lansoprazole Lansoprazole Sulfone
Cmax, ng/mL 1047 (344) 111.2 (41.8) 66.6 (52.9)
Tmax, h 2.0 (0.7) 2.1 (0.8) 1.9 (0.8)
t1/2z, h 2.24 (1.43) 2.31 (1.18) 2.52 (1.54)
MRT, h 3.62 (0.87) – –
AUC0–24, ng/mL/h 3388 (1484) 317.0 (81.2) 231.9 (241.7)
AUC0–∞, ng/mL/h 3496 (1693) – –
CLz/F, L/h 9.96 (3.74) – –
Vz/F, L 32.83 (11.74) – –
t1/2z  = elimination t1/2; MRT = mean residence time; CLz/F = apparent oral clearance; Vz/F = apparent 
volume of distribution.
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Table II.  Pharmacokinetic properties of lansoprazole and its metabolites (5′-hydroxy lansoprazole and lansoprazole sulfone) after 
the administration of a single oral dose (30-mg enteric capsule) of lansoprazole in individual healthy male Chinese 
subjects.
Drug/ 
Metabolite/ Cmax,    AUC0–24, AUC0–∞, CLz/F, 
Subject No. ng/mL Tmax, h t1/2z, h MRT, h ng/mL/h ng/mL/h L/h Vz/F, L
Lansoprazole
   1 1817 1.5 2.32 3.85 6455 6606 4.50 21.82
   2 1129 3 1.02 3.36 3040 3075 9.76 14.31
   3 907 1.5 1.4 2.94 2697 2720 10.98 34.14
   4 1315 1 1.36 2.33 3285 3309 9.07 17.75
   5 956 2 1.1 2.86 2060 2091 14.35 22.78
   6 760 1 1.21 2.19 1997 2023 14.83 25.78
   7 1320 2 2.08 3.77 3801 3826 7.84 23.56
   8 879 2.5 2.05 3.98 4179 4255 6.99 31.47
   9 431 3 1.71 3.19 1810 1823 16.46 40.67
  10 916 1.5 1.66 2.87 3145 3181 9.40 29.57
  11 865 2 2.51 4.43 3232 3351 8.77 50.29
  12 1289 1.5 1.98 3.56 3430 3472 8.60 33.63
  13 1388 2 3.09 5.83 7462 8747 2.33 43.62
  14 1589 1.5 2.02 3.76 5211 5246 5.72 16.69
  15 960 1.5 1.82 3.49 3206 3233 9.25 35.61
  16 743 3 1.84 3.98 2343 2370 12.58 52.90
  17 1379 2 2.99 4.03 3345 3447 8.70 37.54
  18 837 1.5 2.07 3.16 1786 1817 16.51 49.30
  19 747 3 2.82 5.15 2590 2596 11.55 47.09
  20 705 3 7.76 3.67 2690 2723 11.02 28.00
Mean (SD) 1047 (344) 2.0 (0.7) 2.24 (1.43) 3.62 (0.87) 3388 (1484) 3496 (1693) 9.96 (3.74) 32.83 (11.74)
(continued)
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6 Table II  (continued).
Drug/ 
Metabolite/ Cmax,    AUC0–24, AUC0–∞, CLz/F, 
Subject No. ng/mL Tmax, h t1/2z, h MRT, h ng/mL/h ng/mL/h L/h Vz/F, L
5′-Hydroxy 
lansoprazole
   1 103 1.5 1.7 – 280.3 – – –
   2 132 3 1.01 – 426.4 – – –
   3 163 1.5 1.3 – 492.8 – – –
   4 205 1 1.37 – 439.0 – – –
   5 160 2 1.68 – 307.2 – – –
   6 148 1 1.27 – 340.6 – – –
   7 158 2 1.24 – 360.6 – – –
   8 71 2.5 2.06 – 286.0 – – –
   9 77 3 2.39 – 345.9 – – –
  10 133 1.5 3.48 – 395.7 – – –
  11 63 2 4.1 – 298.7 – – –
  12 73 1.5 4.91 – 250.1 – – –
  13 98 2 2.16 – 289.3 – – –
  14 134 1.5 3.31 – 357.9 – – –
  15 57 3 3.16 – 215.4 – – –
  16 83 3 3.73 – 183.7 – – –
  17 115 2 3.48 – 238.1 – – –
  18 118 1.5 1.03 – 263.4 – – –
  19 72 3 1.43 – 217.7 – – –
  20 62 4 1.31 – 351.9 – – –
Mean (SD) 111.2 (41.8) 2.1 (0.8) 2.31 (1.18) – 317.0 (81.2) – – –
(continued)
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Table II  (continued).
Drug/ 
Metabolite/ Cmax,    AUC0–24, AUC0–∞, CLz/F, 
Subject No. ng/mL Tmax, h t1/2z, h MRT, h ng/mL/h ng/mL/h L/h Vz/F, L
Lansoprazole 
sulfone
   1 181.7 1.5 3.77 – 981.0 – – –
   2 38.3 3 0.92 – 65.1 – – –
   3 30.4 1.5 1.15 – 44.8 – – –
   4 31.4 1 0.61 – 59.3 – – –
   5 34.0 2 0.68 – 50.2 – – –
   6 26.9 0.67 2.35 – 42.3 – – –
   7 48.5 2 1.64 – 100.5 – – –
   8 81.6 1.5 3.31 – 485.7 – – –
   9 16.0 1 1.45 – 33.8 – – –
  10 33.7 1 1.46 – 75.2 – – –
  11 34.1 2 2.14 – 126.2 – – –
  12 117.0 1.5 3.23 – 380.9 – – –
  13 56.6 3 6.37 – 410.9 – – –
  14 189.0 1.5 2.60 – 514.1 – – –
  15 119.2 1.5 2.92 – 381.9 – – –
  16 42.4 3 2.56 – 112.7 – – –
  17 136.3 2 1.47 – 340.8 – – –
  18 24.8 1.5 2.19 – 64.9 – – –
  19 53.1 3 4.10 – 271.5 – – –
  20 37.6 3 5.48 – 96.4 – – –
Mean (SD) 66.6 (52.9) 1.9 (0.8) 2.52 (1.54) – 231.9 (241.7) – – –
t1/2z  = elimination t1/2; MRT = mean residence time; CLz/F = apparent oral clearance; Vz/F = apparent volume of distribution.
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The established HPLC-MS/MS method was selective and sensitive for the simulta-
neous determination of lansoprazole, 5′-hydroxy lansoprazole, and lansoprazole sul-
fone concentrations in plasma.
CONCLUSIONS
In these healthy Chinese male volunteers administered a single oral dose of 30-mg 
lansoprazole, absorption of lansoprazole was rapid (mean Cmax, 1047 ng/mL; Tmax, 
~2.0 hours). Its 2 primary active metabolites, 5′-hydroxy lansoprazole and lanso- 
prazole sulfone, were identified in measurable quantities in plasma (Cmax, 111.2 and 
66.6 ng/mL, respectively; Tmax, 2.1 and 1.9 hours). The plasma t1/2z did not appear to 
reflect the duration of suppression of gastric acid secretion: the t1/2z values of lansopra-
zole and its 2 metabolites were ~2 to 2.5 hours, while the acid-inhibitory effect 
lasted >24 hours. Cmax, AUC, and t1/2z of lansoprazole, and especially lansoprazole 
sulfone, varied. Differences in metabolism types and/or genotype of CYP2C19 should 
be taken into account when planning a lansoprazole dosing regimen.
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